Japanese MHLW approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent ... News-Medical.net Abbott (NYSE: ABT) today announced it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation XIENCE PRIME™ Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. Abbott Receives Approval For Xience Prime Everolimus Eluting Stent In Japan Abbott Receives Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent ... |
